Bristol Myers Squibb Operating Income 2010-2022 | BMY

Bristol Myers Squibb annual/quarterly operating income history and growth rate from 2010 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
  • Bristol Myers Squibb operating income for the quarter ending March 31, 2022 was $1.687B, a 33.32% decline year-over-year.
  • Bristol Myers Squibb operating income for the twelve months ending March 31, 2022 was $7.255B, a 279.71% decline year-over-year.
  • Bristol Myers Squibb annual operating income for 2021 was $8.098B, a 217.86% decline from 2020.
  • Bristol Myers Squibb annual operating income for 2020 was $-6.871B, a 238.11% decline from 2019.
  • Bristol Myers Squibb annual operating income for 2019 was $4.975B, a 16.64% decline from 2018.
Bristol Myers Squibb Annual Operating Income
(Millions of US $)
2021 $8,098
2020 $-6,871
2019 $4,975
2018 $5,968
2017 $5,131
2016 $5,915
2015 $2,077
2014 $2,381
2013 $2,891
2012 $4,170
2011 $6,981
2010 $6,071
2009 $5,320
Bristol Myers Squibb Quarterly Operating Income
(Millions of US $)
2022-03-31 $1,687
2021-12-31 $1,858
2021-09-30 $2,157
2021-06-30 $1,553
2021-03-31 $2,530
2020-12-31 $-10,451
2020-09-30 $2,257
2020-06-30 $1,627
2020-03-31 $-304
2019-12-31 $-129
2019-09-30 $1,349
2019-06-30 $1,776
2019-03-31 $1,979
2018-12-31 $1,505
2018-09-30 $2,167
2018-06-30 $517
2018-03-31 $1,779
2017-12-31 $698
2017-09-30 $1,183
2017-06-30 $1,295
2017-03-31 $1,955
2016-12-31 $1,086
2016-09-30 $1,559
2016-06-30 $1,615
2016-03-31 $1,655
2015-12-31 $-410
2015-09-30 $987
2015-06-30 $52
2015-03-31 $1,448
2014-12-31 $-60
2014-09-30 $1,008
2014-06-30 $448
2014-03-31 $985
2013-12-31 $869
2013-09-30 $818
2013-06-30 $530
2013-03-31 $674
2012-12-31 $513
2012-09-30 $571
2012-06-30 $1,059
2012-03-31 $2,027
2011-12-31 $1,717
2011-09-30 $1,767
2011-06-30 $1,768
2011-03-31 $1,729
2010-12-31 $1,593
2010-09-30 $1,581
2010-06-30 $1,531
2010-03-31 $1,366
2009-12-31 $1,252
2009-09-30 $1,477
2009-06-30 $1,419
2009-03-31 $1,172
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $165.407B $46.385B
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
Stock Name Country Market Cap PE Ratio
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.180B 16.07
Biohaven Pharmaceutical Holding (BHVN) United States $10.170B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.223B 0.00
Arcus Biosciences (RCUS) United States $1.792B 45.42
Emergent Biosolutions (EBS) United States $1.625B 6.95
Myovant Sciences (MYOV) United Kingdom $1.313B 0.00
Zymeworks (ZYME) Canada $0.365B 0.00
Gelesis Holdings (GLS) United States $0.122B 0.00
Ambrx Biopharma (AMAM) United States $0.110B 0.00
Enzo Biochem (ENZ) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00